Genmab A/S Stock

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen 11:20:00 2024-06-14 EDT 5-day change 1st Jan Change
1,832 DKK +0.47% Intraday chart for Genmab A/S -5.05% -14.97%

Financials

Sales 2024 * 19.81B 2.84B 3.9B Sales 2025 * 23.61B 3.39B 4.65B Capitalization 118B 16.89B 23.18B
Net income 2024 * 4.67B 670M 920M Net income 2025 * 6.54B 938M 1.29B EV / Sales 2024 * 4.63 x
Net cash position 2024 * 25.89B 3.71B 5.1B Net cash position 2025 * 32.22B 4.62B 6.34B EV / Sales 2025 * 3.62 x
P/E ratio 2024 *
27 x
P/E ratio 2025 *
19.6 x
Employees 2,286
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.51%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Genmab A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating MT
Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study MT
Transcript : Genmab A/S - Special Call
Genmab A/S Announces Data from the Phase 2 Innovatv 207 Trial, Investigating Tisotumab Vedotin CI
Genmab A S and BioNTech SE Announces Initial Data from the Ongoing Phase 2 Trial CI
Genmab Announces Initial Data from Phase 2 Cancer Treatment Trial MT
Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma CI
Genmab A/S and Biontech SE Announce Initial Data from the Phase 2 Gct1046-04 Trial (NCT05117242) Evaluating Acasunlimab CI
Genmab A/S Reaffirms Financial Guidance for 2024 CI
Genmab A/S completed the acquisition of ProfoundBio, Inc. CI
Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation' MT
Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50% MT
Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association Congress CI
GENMAB : A good start to 2024; guidance unchanged Alphavalue
More news
1 day+0.47%
1 week-5.05%
Current month-5.39%
1 month-9.51%
3 months-12.32%
6 months-14.93%
Current year-14.97%
More quotes
1 week
1 811.50
Extreme 1811.5
1 932.00
1 month
1 811.50
Extreme 1811.5
2 088.00
Current year
1 811.50
Extreme 1811.5
2 227.00
1 year
1 811.50
Extreme 1811.5
2 814.00
3 years
1 811.50
Extreme 1811.5
3 327.00
5 years
1 082.50
Extreme 1082.5
3 327.00
10 years
204.80
Extreme 204.8
3 327.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 98-12-31
Director of Finance/CFO 46 06-12-31
Chief Operating Officer 53 20-03-22
Members of the board TitleAgeSince
Chairman 63 16-12-31
Director/Board Member 73 03-10-31
Director/Board Member 64 15-12-31
More insiders
Date Price Change Volume
24-06-14 1,832 +0.47% 150,944
24-06-13 1,824 -1.25% 165,225
24-06-12 1,847 -2.48% 278,923
24-06-11 1,894 -1.48% 164,865
24-06-10 1,922 -0.39% 101,654

Delayed Quote Nasdaq Copenhagen, June 14, 2024 at 11:20 am

More quotes
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,832 DKK
Average target price
2,464 DKK
Spread / Average Target
+34.46%
Consensus